GSK's Zejula (niraparib) Receives FDA's Approval for Late-line Treatment in Women with Recurrent Ovarian Cancer
Shots:
- The approval for the expanded indication is based on P-II QUADRA study assessing Zejula (niraparib) in 463 patients relapsed- high-grade serous epithelial ovarian- fallopian tube- or primary peritoneal cancer prior treated with >3 CT regimen and whose cancer is associated with homologous recombination deficiency (HRD)
- The P-II QUADRA study results demonstrated ORR (24%) with mDOR (8.3 mos.). Additional analyses showed: BRCA+ platinum-sensitive disease- ORR (39%); tBRCA+ platinum-resistant disease- ORR (29%); tBRCA+ platinum-refractory disease- ORR (19%); non-BRCA mut- GIS-positive- platinum-sensitive disease- ORR (20%)
- Zejula (qd) is a PARP inhibitor currently being evaluated in multiple studies as monothx in P-III PRIMA study and FIRST study and as a combination with bevacizumab in P-II OVARIO study. The Myriad myChoice companion diagnostic test was utilized during the P-II QUADRA study
Click here to read full press release/ article
Ref: Businesswire | Image: GSK
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com